Loading…
Loading…
HOUSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced its forward-looking strategy for the third and fourth quarters of 2026, centered on deepening relationships with clinical trial sponsors and Contract Research Organizations (CROs). Neutra Corp has committed its full resources to the growth and expansion of Neutra Life Sciences, its wholly owned clinical research Site Management Organization (SMO) subsidiary, as the Company's primary strategic priority for the remainder of 2026 and beyond.
HOUSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced a series of operational milestones at its wholly owned subsidiary, Neutra Life Sciences, a clinical research Site Management Organization (SMO). Following its 2025 launch and early-stage growth, Neutra Life Sciences has proven its operational excellence with multiple clinical trial.
HOUSTON, TX, Dec. 29, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neutra Corporation (OTC PINK:NTRR), an emerging health and wellness research and development company, reflects on the 2023 year and plans for moving forward in 2024. In the previous press release, Neutra announced a medium-term management plan to meet the rapidly increasing demand for the company's modern approach to specialty health and wellness solutions.
HOUSTON, TX, Oct. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Neutra Corporation (OTC PINK: NTRR), an emerging health and wellness research and development company, announces today a two-year, medium-term management plan in order to meet the rapidly increasing demand for the company's modern approach to specialty health and wellness solutions. The strategic plan helps strengthen the shift towards the service business to grow its health and wellness portfolio and formalizes its pursuit of consulting services aimed at clinical research standards and education. The “Clinical Foundations” service model draws upon the multiple advances in the company's core products and will help cement its leadership of value creation in the specialty healthcare and wellness space.
KATY, TX / ACCESSWIRE / September 14, 2021 / Neutra Corp. subsidiary VIVIS has signed a groundbreaking letter of intent (LOI) with a Houston clinical research company that, if it comes to a successful conclusion, would lead to testing hemp-based cannabinoids to treat COVD-19. Under the LOI's provisions, VIVIS will now determine the feasibility of working with Mercury Clinical Research to start phase 1 clinical trial on CBD efficacies in combating SARS-COVID-2.
KATY, TX / ACCESSWIRE / September 13, 2021 / Neutra Corp. subsidiary VIVIS has signed a groundbreaking letter of intent (LOI) with a Houston clinical research company that, if it comes to a successful conclusion, would lead to testing hemp-based cannabinoids to treat COVID-19. Under the LOI's provisions, VIVIS will now determine the feasibility of working with Mercury Clinical Research to start phase 1 clinical trial on CBD efficacies in combating SARS-COVID-2.
KATY, TX / ACCESSWIRE / August 16, 2021 / Neutra Corp. (OTC PINK:NTRR) continues to make substantial progress in securing distribution for its wholly-owned subsidiary VIVIS' CBD products. Since announcing this strategy in January, Neutra management has successfully placed VIVIS in Festival Foods, a large 35 store regional supermarket chain.
KATY, TX / ACCESSWIRE / August 2, 2021 / Neutra Corp. (OTC PINK:NTRR) announces it has been officially accepted in a well-known Wisconsin grocery company for Neutra's CBD products to be sold at its stores, starting initially with the chain's flagship location on August 9, 2021. This means that Festival Food shoppers can find and buy VIVIS-branded items at the company's Onalaska store, about halfway between Madison, Wisconsin, and Minneapolis.
No recent filings indexed.